Skip to main content
Premium Trial:

Request an Annual Quote

Cytyc to Buy Digene for $77M; Cervical Cancer Diagnostics Will Be One Focus

NEW YORK, Feb. 19 - Sample preparation firm Cytyc will acquire diagnostics company Digene in a stock and cash deal worth $77 million, the companies said on Tuesday


Under the deal, Cytyc will issue 23 million shares of common stock, and Digene shareholders will receive $4.00 in cash and 1.1969 shares of Cytyc for each share of Digene owned.


Based on Friday's closing chare price on the Nasdaq, the deal will provide shareholders with a 13 percent premium.


The transaction will result in a one-time charge of up to $65 million and is subject to the tender of more than 50 percent of Digene's stock. It is expected to close during the second quarter of the year.


Both Cytyc, of Boxborough, Mass., and Digene develop diagnostics related to cervical cancer: Cytyc is working on an automated system for pap testing, and Digene's test detects human papilloma virus, which is linked to cervical cancer.


The acquisition will allow the Cytyc collection system and the Digene hybrid capture testing technology to be combined, said Cytyc chief executive officer Patrick Sullivan in a statement. According to the company, that combined approach has shown to be useful for patients with borderline cytology results.


Digene, based in Gaithersburg, Md., uses genomics research to develop tests for sexually transmitted diseases and other conditions.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.